Kidney fibrosis is the final common of all progressive chronic kidney diseases, of which diabetic nephropathy is the leading cause. Endothelial-to-mesenchymal transition (EndMT) has emerged as one of the most important origins of matrix-producing fibroblasts. Dipeptidyl peptidase-4 (DPP-4) inhibitors have been introduced into the market as anti-diabetic drugs. Here, we found that the DPP-4 inhibitor linagliptin ameliorated kidney fibrosis in diabetic mice without altering their blood glucose levels associated with the inhibition of EndMT and the restoration of microRNA29s. 
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Introduction
Diabetic nephropathy is a leading cause of kidney disease, which progresses into end-stage renal disease, requiring kidney replacement therapy (1; 2). Glycemic control could be essential for therapies combatting diabetic nephropathy, although normalizing the blood glucose levels in such patients with appropriate monitoring is challenging (2) . Therefore, to prevent/retard diabetic nephropathy, in addition to achieving proper glycemic control, strategies that are not directly related with blood glucose normalization are required.
Fibrosis in the kidney is the final common pathway of progressive kidney diseases and results in the destruction of the kidney structure and the deterioration of the kidney filtration function (3) (4) (5) (6) (7) (8) . Kidney fibrosis is caused by prolonged injury associated with the dysregulation of the normal wound healing process and an excess accumulation of extracellular matrix. Kidney fibroblasts play an important role in this fibrotic process, but the origin of the fibroblasts remains unclear and has become the focus of intense debate (2; 9) . A significant heterogeneity of matrix-producing fibroblasts is thought to exist (2) , and diverse origins for fibroblasts have been described, such as residential fibroblasts or pericytes, epithelial-to-mesenchymal transition, and endothelial-to-mesenchymal transition (EndMT) (2) . Among these diverse origins of matrix-producing fibroblasts, EndMT seems to be an important origin of myofibroblasts or activated fibroblasts (9) .
Dipeptidyl peptidase (DPP)-4 inhibitors enhance the activity of endogenous glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (10) , which have emerged as important prandial stimulators of insulin secretion and have many physiological actions (10; 11) . Additionally, DPP-4 is distributed throughout the body The immunolabeled sections were analyzed by fluorescence microscopy (BioZero, Keyence, Osaka, Japan). For each mouse, 300x magnification pictures were obtained from 6 different areas, and quantification was performed.
Morphological evaluation
The glomerular surface area was calculated in 10 glomeruli per mouse using ImageJ software. To evaluate the mesangial matrix area (%), we utilized a point counting method. We analyzed 10 PAS-stained glomeruli from each mouse on a digital microscope screen grid containing 540 (27x20) points in Adobe Photoshop Element
The number of grid points in the mesangial area (both matrix and cells) was divided by the total number of points in the glomerulus to obtain the percentage of relative mesangial matrix area in a given glomerulus. Masson's trichrome-labeled sections were imaged and analyzed by ImageJ software, and fibrotic areas were quantified. In each mouse, 6 pictures (100x magnification) were evaluated.
Immunohistochemistry
Deparaffinized (2 min in xylene, four times; 1 min in 100% ethanol, twice; 30 s in 95% ethanol, 45 s in 70% ethanol, and 1 min in distilled water) mouse kidney sections were utilized for DPP-4 labeling. Immunohistochemistry was performed with a Vectastain ABC kit (Vector Laboratories, Burlingame, CA). The DPP-4 primary antibody was diluted 1:100. In negative controls, the primary antibody was omitted and replaced with blocking solution.
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In vitro EndMT
Human dermal microvascular endothelial cells (HMVECs, Lonza, Basel, Switzerland) cultured in EGM medium were used in this experiment. When the HMVECs on the adhesion reagent (Kurabo medical, Osaka, Japan) reached 70% confluence, 5 ng/ml recombinant human TGF-β2 for 48 h was placed in the experimental medium (HuMedia-MVG in serum-free RPMI at a 1:3 ratio) with or without linagliptin (100 nM) preincubation for 2 h. In control well, vehicle (DMSO) was added (3x10 -5 dilution of DMSO in final concentration). The protein lysate was harvested for western blot analysis.
Wound healing assay
The passaged HMVECs were placed in 6-well plates and cultured with EGM-2 until reaching 70%-80% confluence, and then the cells treated with TGF-β2 (2.5 ng/ml) in the presence or absence of linagliptin (100 nM) were incubated with a medium containing HuMedia MVG and RPMI1640 (1:3). At the same time, the control group was incubated in the same medium without TGF-β2 or linagliptin. In control well, vehicle (DMSO) was added (3x10 -5 dilution of DMSO in final concentration). Using a pipette tip at an angle of approximately 30°, each well received a straight scratch, simulating a wound. After 24 h and 48 h had passed, the number of cells that migrated into the wounded area was counted under a light microscope. Six different areas were evaluated in each group, and the experiment was repeated twice with similar results.
Cell migration Boyden chamber assay
The bottom side of the migration chamber (Cell Culture Insert, BD Falcon, San Jose,
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California) was coated with Matrigel (BD), and 1000 HMVECs were passaged in the upper migration chamber. Twenty-four hours after passage, the medium was changed to the experimental medium (1:3 HuMedia-MVG: RPMI1640) in both the upper and the bottom wells. Subsequently, cells were exposed to TGF-β2 in the presence or absence of linagliptin (100 nM), while the control group was incubated with the same medium, lacking TGF-β2 and linagliptin. In control well, vehicle (DMSO) was added (3x10 -5 dilution of DMSO in final concentration). After 48 h, the cells were washed with PBS, followed by fixation with formaldehyde (3.7% in PBS) at room temperature for 2 min.
After washing twice with PBS, the cells were permeabilized with 100% methanol for 20 min at room temperature. Then, the cells were washed twice with PBS and stained with hematoxylin-eosin. After scraping off the non-migratory cells (upper well) with a cotton swab, the number of migrated cells was counted under a light microscope. Six different areas were evaluated in each group, and the experiment was repeated twice with similar results.
Western blotting
The protein lysates were denatured by boiling in sodium dodecyl sulfate (SDS) sample buffer at 100 °C for 5 minutes and then centrifuged (17,000 ×g for 10 minutes at 4 °C); subsequently, the supernatant was separated on SDS-polyacrylamide gels. Separated 
mRNA array analysis
The total RNA was isolated using a commercially available kit (RNeasy Mini Kit; QIAGEN GmbH, Hilden, Germany). The concentration of RNA was quantified by photometry at 260/280 nm, and the quality of the RNA was determined by the ratio of the 18S/28S ribosomal band intensities in an ethidium bromide-containing 1% agarose gel after electrophoresis. The sense cDNA was prepared using an Ambion® WT Expression Kit (Ambion, Austin, TX), and target hybridizations were performed using a Mouse Gene 1.0 ST Array (Affymetrix, Santa Clara, CA), according to the manufacturer's instructions. Hybridization was performed for 17 h at 45 °C in a GeneChip® Hybridization Oven 640 (Affymetrix). After washing and staining in a GeneChip® Fluidics Station 450, hybridized cDNAs were detected using the GeneChip® Scanner 3000. The digitalized image data were processed using the GeneChip® Operating Software (GCOS) version 1.4. Because replicate assays were not performed, the signal intensities of the selected genes that were up-regulated or down-regulated by at least two-fold compared with a control group were extracted using GeneSpring GX software package version 12.5 (Agilent Technologies, Santa Clara, Page 9 of 40 Diabetes CA). After hierarchical clustering, the results were illustrated as a heat map. Ingenuity
Pathway Analysis (IPA; Ingenuity Systems Inc., Redwood City, CA) was used to select the specific function-related genes.
microRNA array analysis
Total RNA was isolated using the miRNeasy Kit (Qiagen) following the manufacturer's instructions. Quality-confirmed total RNA samples were assayed and qualified in duplicate using the microRNA microarray. The input for the Agilent microRNA labeling system was 100 ng total RNA. Dephosphorylated and denatured total RNA was labeled with cyanine 3-pCp and subsequently hybridized to the Agilent mouse microRNA microarray release version 15 using the microRNA Complete Labeling and Hyb Kit (Agilent Technologies, Inc., Santa Clara CA). Following hybridization for 20 h, the slides were washed with Gene Expression Wash Buffer Kit (Agilent) and measured using an Agilent Scanner G2565BA. Agilent Feature Extraction Software version 9.5.1
and GeneSpring GX software version 12.5 (Agilent) were used for data processing, analysis, and monitoring.
microRNA isolation and qPCR
Frozen kidney tissues (one each from a control, diabetic, and linagliptin-treated diabetic mouse; samples were kept on -70 °C) were first placed on the RNA later UAGCACCAUUUGAAAUCGGUUA for Mm_miR-29c. All experiments were performed in triplicate, and Hs_RNU6-2_1 (Qiagen) was utilized as an internal control.
Transfection
For the transfection studies, HMVECs, which were maintained in EBM-2 medium supplemented with EGM TM -2 (Lonza, USA), were passaged in 6-well plates with non-proliferative medium (HuMedia-MVG and RPMI at a ratio of 1:3). The HMVECs were transfected with 100 nM of antagomir○ R for miR-29a, miR-29c, amiR-29a+c (Fasmac, Japan), miR-29b inhibitor (Quiagen), or mimetics for miR29s (29a-3p:
UAGCACCAUCUGAAAUCGGUUA, 29b-3p:
UAGCACCAUUUGAAAUCGGUUA) using Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions.
The cells were incubated for 6 h with Lipofectamine and the anti-microRNA complex in antibiotic-free medium, after which the medium was replaced with fresh medium before the cells were incubated for another 48 h. Upon the termination of the 
Luciferase assay
For the luciferase assay to analyze the activity of 3'UTR in human DPP-4, we cloned the fragment of human DPP-4 3'UTR sequence by PCR using the primer set (Fw: 
Statistical analysis
The data are expressed as the means ± s.e.m. The non-parametric Mann-Whitney U test was used to determine significance, which was defined as P < 0.05, if not specifically mentioned. GraphPad Prism software (Ver 5.0f) was used for the statistical analysis.
Page 12 of 40 Diabetes
Results
Linagliptin restored the normal kidney structure of STZ-induced diabetic kidney fibrosis in CD-1 mice
We utilize a fibrotic diabetic kidney disease model, STZ-induced diabetes in male CD-1 mice. The immunohistochemistry analysis revealed robust DPP-4 immunolabeling in the glomerular basement membrane, tubules, and peritubular vascular cells in the kidney of STZ-induced diabetic CD-1 mice when compared with control CD-1 mice ( Fig. 1 A, B) . Such peritubular vascular cells were likely endothelial cells upon evaluation by immunofluorescence microscopy ( Fig. 1 C, D, E) . Western blot analysis using whole kidney revealed that, in the kidneys of diabetic mice, the DPP-4 protein levels were up-regulated compared with control kidneys (Fig. 1 F, G) . Fig. 1 ), and at 24 weeks after the initiation of diabetes, diabetic mice exhibited severe fibrosis when compared with control mice (Fig. 2 A, B, D, E) . Linagliptin-treated diabetic mice exhibited restored normal kidney structures (Fig. 2 C, F) . Morphometric analysis of the kidneys revealed that diabetic mice displayed significantly enlarged glomeruli, mesangial expansion, and relative areas of Masson-trichrome-positive interstitial fibrosis (Fig. 2 G, H, I ), while linagliptin restored normal kidney histology and normal architecture (Fig. 2 G, H, I ). Urine albumin levels were elevated in STZ mice, and linagliptin treatment suppressed the trend of the urine albumin levels (Fig. 2J) as observed in human clinical trial (21) . These antifibrotic effects of linagliptin in diabetic mice are associated with suppressed trend of TGFβ1 and DPP-4, and significant
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suppression of TGFβ2 protein levels in kidney ( Fig. 2 K-N) . Linagliptin inhibited DPP-4 mRNA (Fig. 2O) and diabetes-enhanced DPP-4 activity in kidney and plasma of diabetic mice (Fig.2 P and Q) When compared with control mice, diabetic CD-1 mice exhibited lower blood pressure, lighter body weight, higher blood sugar, and increased kidney and liver weight (Fig. 3 A, B, C, D, E) . Linagliptin treatment in STZ-induced diabetic CD-1 mice caused no alteration in blood pressure, body weight, blood sugar level, or organ weight (for kidney, liver, and heart) when compared with untreated diabetic mice ( Fig. 3 A, B , C, D, E). The heart weight was lighter in all diabetic mice but showed insignificant changes in all groups analyzed (Fig. 3F) .
The anti-fibrotic effects of linagliptin were associated with the inhibition of
EndMT in diabetic kidneys
Kidney fibroblasts play essential roles in kidney fibrosis and originate from diverse sources (2; 9; 22). In our analysis, we analyzed EndMT, a recently described important source of kidney fibroblasts (2; 9; 23). When EndMT was analyzed by quantifying cells that co-expressed endothelial marker CD31 and a mesenchymal marker, either α-smooth muscle actin (SMA) or FSP1, diabetic CD-1 mice exhibited a significantly increased number of cells in the process of the EndMT when compared with control kidneys (Fig. 4 A, B, D, E, F, H) . Linagliptin-treated mice exhibited significantly fewer cells undergoing EndMT in the kidney when compared to untreated diabetic mice (Fig. 4 C, D, G, H) .
Linagliptin inhibited EndMT and apoptosis in cultured endothelial cells
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In cultured endothelial cells, TGF-β2 induced the suppression of CD31 with concomitant upregulation of SM22α in HMVECs, suggesting that TGF-β2 induces EndMT (Fig. 5 A, B, C) ; TGF-β2-induced EndMT was inhibited by linagliptin pre-treatment (Fig. 5 A, B, C) . Wound healing cell invasion assays revealed that TGF-β2 also induced the migration of fibroblast-like EndMT cells (Fig. 5 D, E, J, G,   H) , while linagliptin inhibited the invasion of those cells (Fig. 5 F, I, J) . The Boyden chamber cell migration assay also revealed that linagliptin inhibited the endothelial cells' transmigration through Matrigel (Fig. 5 K-N) . When analyzing the molecular mechanisms of TGF-β2 induced EndMT effects, we found that linagliptin inhibited TGF-β2-induced smad3 phosphorylation in endothelial cells (Fig. 5O) . Linagliptin inhibited TGF-β2-induced protein expression, mRNA expression, and activity of DPP-4 in endothelial cells (Fig. 5 P- 
R). Linagliptin and generic DPP-4 inhibitor KR62436
inhibited TGF-β2-induced endothelial cell apoptosis (Supplementary Fig. 2 ).
Linagliptin inhibited profibrotic programing in the diabetic kidney
A heat map indicated the differences among controls, diabetic mice, and diabetic mice treated with linagliptin ( Supplementary Fig. 3A) . Some groups of genes trended altered in the diabetic mouse and restored in the linagliptin-treated mouse (Supplementary Fig. 3A) . To focus on fibrosis, we selected fibrosis-associated genes based in the Ingenuity Pathways Analysis database and plotted them in a scattered format (Supplementary Fig. 3B ). Compared with controls, 13 genes were up-regulated, and 2 genes were down-regulated in the diabetic mouse (Supplementary Fig. 3C ).
However, the expression of these genes trended to be reversed into normal levels after 
Role of microRNA29 family suppression in the DPP-4 induction of diabetic kidney
Finally, to identify the underlying mechanisms of how DPP-4 is increased in diabetic kidney, we analyzed the microRNA profiles of the animals and found that the microRNA 29 family tended to be suppressed in diabetic mice kidneys when compared with control kidneys (Fig. 6A : though no significant difference by Welch's test yet).
According to the prediction of microRNA targets by TargetScan (http://www.targetscan.org/vert_60/), DPP-4 may be regulated by the microRNA 29
family. Quantitative analysis revealed that microRNAs 29 a, b, and c were suppressed in the diabetic kidney when compared with control kidneys and linagliptin restored such diabetes-suppressed microRNA 29s (Fig. 6 B, C, D) . Similarly TGF-β2-suppressed microRNA29s were restored by linagliptin in vitro analysis ( Supplementary Fig. 4 ).
When an antagomiR ○ R for microRNA 29a was transfected into endothelial cells, DPP-4 protein levels were indeed increased ( Fig. 6 E, F) , whereas microRNA 29c antagomiR ○ R transfection unchanged DPP-4 level (Fig. 6 E, F) . The co-transfection of antagomiRs ○ R for microRNAs 29a and 29c resulted in persistently higher DPP-4 protein levels in the endothelial cells compared with controls ( Fig. 6 E, F) . In addition, the inhibitor ○ R for microRNA 29b induced DPP-4 protein expression in HMVECs (Fig.   6 G, H) , suggesting that microRNAs, specifically the microRNA 29 family, regulate DPP-4 in the diabetic kidney. TGF-β2-enhanced DPP-4 protein expression was significantly suppressed by microRNA 29b mimetics and some trend of suppression was found in microRNA 29a,c mimetics-transfected cells (Fig. 6 I and J) .
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TGF-β2-induced EndMT and endothelial cell migration was largely inhibited by microRNA29s mimetic transfection (Fig. 6 I, K-T) . In contrast antagomiRs ○ R and inhibitor ○ R for microRNA29s induced EndMT phenotype and migration (Supplementary Fig. 5 ). TGF-β2-stimulated luciferase activity of pmirGLO Dual-Luciferase miRNA Target Expression Vector containing 3'UTR fragment of DPP-4, where microRNA 29 binding site was involved, were significantly suppressed by miR29 mimetics (Fig. 6U) . In contrast, antagomiR ○ R or inhibitor ○ R of microRNA29s significantly induced DPP-4 3'UTR luciferase activity (Fig. 6V) .
Discussion
Both the inhibition of kidney fibrosis and the restoration of normal kidney structure are fundamental processes to research for developing therapies to combat progressive chronic kidney disease, including diabetic nephropathy. Although kidney fibroblasts have been implicated in the pathogenesis of kidney fibrosis, it would be challenging to inoculate only kidney fibroblasts as therapeutic targets. In our analysis, DPP-4 inhibition by linagliptin in the diabetic kidney seems to be a powerful therapy that inhibits the fibroblast-activating process.
We found that DPP-4 protein expression was increased in the whole kidney activity could be a potential target for combatting such liver diseases (37) . Further study is required to determine whether DPP-4 activity is greater in type 1 or type 2 diabetic kidney diseases, or in other fibrotic chronic and acute diseases, including kidney disease, in humans.
In our analysis, linagliptin inhibited kidney fibrosis and restored normal kidney structure. Even though convincing, there are several limitations. First, the concentration we used was very high (5mg/kgBW) when compared to that used in clinic Finally analyze for distinct roles of each microRNA29s in the regulation of DPP-4 and kidney fibrosis would require further investigation.
Diabetic kidney disease represents a serious health problem worldwide and can develop into end-stage renal disease, which requires kidney replacement therapy.
Progressive kidney fibrosis determines residual kidney function, and the restoration of the normal architecture to the fibrotic kidney would constitute a fundamental therapy.
We reported here that the anti-fibrotic effects of linagliptin are beneficial for diabetic kidney disease, regardless of the blood sugar levels, via the suppression of the activated fibroblast-generating EndMT pathway at least in part. Linagliptin may be safe for use among kidney disease patients, given its ability to be exclusively eliminated via the bile; this specificity suggests that this DPP-4 inhibitor has potential utility for therapeutic use in combatting kidney fibrosis in diabetes. Densitometric analysis was also performed and relative value against actin levels (n=3). 
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